Geftinat 250mg

Gefitinib is a targeted therapy medication that offers significant benefits and features in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with specific genetic mutations such as epidermal growth factor receptor (EGFR) mutations. As a tyrosine kinase inhibitor (TKI), gefitinib selectively targets and inhibits the activity of the EGFR protein, which is often overexpressed or mutated in NSCLC, leading to uncontrolled cell proliferation and tumor growth. By blocking EGFR signaling pathways, gefitinib effectively suppresses tumor cell growth and induces apoptosis, resulting in tumor shrinkage and improved progression-free survival in patients with EGFR-mutated NSCLC.

Moreover, gefitinib offers several advantages over traditional chemotherapy, including oral administration, favorable tolerability, and fewer systemic side effects. Its targeted approach allows for selective inhibition of cancer cells harboring EGFR mutations while sparing normal cells, thereby minimizing adverse effects commonly associated with conventional chemotherapy, such as myelosuppression and gastrointestinal toxicity. Additionally, gefitinib has demonstrated efficacy in patients who have progressed on prior chemotherapy regimens, providing a valuable treatment option for those with advanced or metastatic NSCLC who may have limited therapeutic alternatives.